IgA-inducing protein (IGIP)

IgA-inducing protein (IGIP) is a secreted molecule expressed mainly by dendritic cells in mucosal tissues. It plays a crucial role by inducing immunoglobulin A (IgA) production in B cells, thereby enhancing the mucosal immune response. IGIP acts by promoting class switch recombination to IgA in B lymphocytes—a process critical for adaptive immunity at mucosal surfaces. Its expression can be influenced by microbial signals and cytokines in the gut-associated lymphoid tissue (GALT), and its activity supports robust immune protection against pathogens by increasing IgA levels. While not a classical cytokine, IGIP functions in a similar manner to other mucosal immune inducers, such as BAFF, APRIL, and TGF-β, but is distinct in its specificity for the IgA class switch pathway and mucosal tissue expression[2]. There is currently no known drug that targets IGIP, nor are there widely recognized safety concerns or biomarkers linked to clinical modulation of IGIP. Its primary relevance is in basic immunology and potential therapeutic modulation of mucosal immunity.

Other names

IGIPC5orf53LOC492311IgA-inducing protein homologIgA-inducing protein homolog (Bos taurus)

Not applicable, as no drugs are currently known to directly target this molecule.